Premium
Decreased INR after acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir co‐administration
Author(s) -
LorenzoPinto A.,
GiménezManzorro Á.,
RodríguezGonzález C. G.,
AhumadaJiménez A.,
HerranzAlonso A.,
MarzalAlfaro M. B.,
SanjurjoSáez M.
Publication year - 2016
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12403
Subject(s) - ombitasvir , dasabuvir , ritonavir , paritaprevir , medicine , acenocoumarol , pharmacy , pharmacology , virology , ribavirin , warfarin , human immunodeficiency virus (hiv) , hepatitis c virus , viral load , virus , antiretroviral therapy , atrial fibrillation , family medicine
Summary What is known and objective Limited data are available on co‐administration of acenocoumarol with direct‐acting antiviral agents for chronic hepatitis C virus infection. Case summary We report a case of a patient who required a significant increase in acenocoumarol weekly dose probably due to an interaction with ombitasvir/paritaprevir/ritonavir and/or dasabuvir. A causality assessment of the drug–drug interaction leading to a reduced INR was conducted according to the Naranjo algorithm. A score of 6 suggested that the adverse drug reaction was probable. What is new and conclusion Because of possible INR abnormalities during the concomitant use of acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir, clinicians should closely monitor INR values.